A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Modern Retina Spring 2022
In the face of the COVID-19 pandemic, the procedure required adjustments.
The implant achieves impressive efficacy and reduces treatment burden.
Investigational pipeline provides promise for an unmet need.
The first FDA-approved bispecific antibody for the eye targets two leading causes of vision loss.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5